Opportunity Information: Apply for PA 13 093
Apply for PA 13 093
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Development and Commercialization of Technologies to Create, Characterize or Improve Animal Models of Human Disease (STTR)(R41/R42)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.351 Research Infrastructure Programs.
- This funding opportunity was created on Jan 25, 2013 and posted on Jan 25, 2013.
- Applicants must submit their applications by Jan 7, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses.
- Other Eligible Applicants include the following Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
This grant opportunity, PA 13-093, is a National Institutes of Health (NIH) Small Business Technology Transfer (STTR) program announcement that funded early-stage and later-stage small business projects aimed at improving animal models of human disease. It was run through the NIH Office of Research Infrastructure Programs (ORIP), specifically the Division of Comparative Medicine (DCM), which focuses on supporting national resources that create, develop, preserve, and distribute high-quality animal models and related biological materials for broad use by the biomedical research community. The central idea of the opportunity is that better tools and technologies around animal models directly strengthen biomedical research infrastructure and make it easier for scientists to tackle new and emerging challenges in human and animal health.
The FOA invited small business concerns to propose innovative, commercially oriented technologies that would advance how animal models are created, characterized, maintained, improved, and used. In practice, that means projects could focus on new methods or platforms that make animal colonies healthier or easier to manage (husbandry-focused technologies), improve the consistency and quality of animal models, or increase the scientific value of those models through better characterization and measurement. The announcement also emphasized “related biological materials,” which commonly includes things like tissues, cell lines, embryos, gametes, microbiome-related materials, or other model-associated resources that are stored, shared, and used across laboratories. The explicit emphasis on development and commercialization means applicants were expected to move beyond basic research and toward products, services, or enabling technologies that could realistically be adopted by the broader research community.
Because this is an STTR mechanism, the program was structured to support formal collaboration between a small business and a nonprofit research institution (such as a university or research institute), combining the business goal of commercialization with the research strengths of the partnering institution. The funding mechanism listed is R41/R42, which corresponds to the phased STTR approach: Phase I (R41) generally supports feasibility and proof-of-concept work, while Phase II (R42) supports more advanced R&D aimed at developing a prototype, refining the technology, and positioning it for commercialization or broad implementation. The FOA sits within the health funding activity category and is associated with CFDA 93.351 (Research Infrastructure Programs), highlighting that the purpose is not only scientific discovery but also strengthening the tools and platforms that enable the wider biomedical ecosystem.
Eligibility was limited to small businesses. Foreign (non-U.S.) entities were not eligible to apply, and non-U.S. components of U.S. organizations were also not eligible. However, “foreign components” as defined by NIH policy could be allowed in some circumstances, which typically means discrete parts of the project may occur outside the U.S. if they are well-justified and compliant with NIH rules. The FOA did not require cost sharing or matching funds, which can be important for early-stage companies that may not have substantial non-dilutive capital available.
From an administrative standpoint, this opportunity was categorized as a discretionary grant program. It was posted and created on January 25, 2013, with an original closing date of January 7, 2016, and it was archived on February 7, 2016, meaning it is no longer open for new applications under that announcement number. The sponsor agency was the NIH, and the full announcement was hosted on the NIH grants guide site. For access issues, the contact provided was the NIH Office of Extramural Research (OER) webmaster.
Overall, the opportunity was designed to catalyze small business-led innovation that makes animal disease models and associated resources more reliable, more informative, and easier to use at scale, while also pushing those innovations toward commercialization so they could be broadly deployed across biomedical research programs.
FAQs: NIH STTR PA 13-093 (Animal Models of Human Disease)
What is PA 13-093?
PA 13-093 was a National Institutes of Health (NIH) Small Business Technology Transfer (STTR) program announcement that supported small business projects to improve animal models of human disease and related biological materials, with an emphasis on development and commercialization.
Which NIH organization ran this opportunity?
The opportunity was run through the NIH Office of Research Infrastructure Programs (ORIP), specifically the Division of Comparative Medicine (DCM).
What was the main purpose of this funding opportunity?
The central purpose was to strengthen biomedical research infrastructure by supporting better tools and technologies for creating, characterizing, maintaining, improving, and using high-quality animal models and associated biological materials that the broader biomedical research community can use.
What kinds of projects were encouraged?
The FOA invited innovative, commercially oriented technologies that advance how animal models are created, characterized, maintained, improved, and used. Examples described at a high level included husbandry-focused technologies that improve colony health or manageability, tools that increase consistency and quality of models, and methods that expand the scientific value of models through better characterization and measurement.
What does “related biological materials” mean in this announcement?
The announcement emphasized related biological materials associated with animal models. The description indicates these commonly include tissues, cell lines, embryos, gametes, microbiome-related materials, and other model-associated resources that can be stored, shared, and used across laboratories.
Was this opportunity focused on basic research or commercialization?
It emphasized development and commercialization. Applicants were expected to move beyond basic research toward products, services, or enabling technologies that could realistically be adopted by the broader research community.
What funding mechanism was used?
The funding mechanism was NIH STTR R41/R42, which is a phased approach: Phase I (R41) generally supports feasibility and proof-of-concept work, and Phase II (R42) supports more advanced R&D such as developing and refining a prototype and positioning the technology for commercialization or broad implementation.
Why was this an STTR opportunity rather than another NIH mechanism?
As an STTR program, it was structured to support formal collaboration between a small business and a nonprofit research institution (such as a university or research institute), combining commercialization goals with research strengths from the partnering institution.
Who was eligible to apply?
Eligibility was limited to small businesses (small business concerns).
Could a nonprofit research institution apply as the lead applicant?
Based on the STTR structure described, the small business was the eligible applicant, and the program supported collaboration with a nonprofit research institution partner.
Were foreign (non-U.S.) entities eligible to apply?
No. Foreign (non-U.S.) entities were not eligible to apply under this announcement.
Could a U.S. organization include work performed outside the United States?
Non-U.S. components of U.S. organizations were not eligible. However, the description notes that “foreign components” as defined by NIH policy could be allowed in some circumstances, typically meaning discrete parts of the project may occur outside the U.S. if well-justified and compliant with NIH rules.
Was cost sharing or matching required?
No. The FOA did not require cost sharing or matching funds.
What is the CFDA number associated with this opportunity?
The opportunity is associated with CFDA 93.351 (Research Infrastructure Programs).
How was this opportunity categorized administratively?
It was categorized as a discretionary grant program.
When was PA 13-093 posted and when did it close?
It was posted and created on January 25, 2013. The original closing date was January 7, 2016.
Is PA 13-093 still open for applications?
No. It was archived on February 7, 2016, which means it is no longer open for new applications under that announcement number.
Who was the sponsor agency?
The sponsor agency was the National Institutes of Health (NIH).
Where was the full announcement hosted?
The full announcement was hosted on the NIH Grants Guide site.
Who was listed as the contact for access issues?
For access issues, the contact provided was the NIH Office of Extramural Research (OER) webmaster.
What broader impact was this FOA trying to achieve?
The opportunity aimed to catalyze small business-led innovation that makes animal disease models and associated resources more reliable, more informative, and easier to use at scale, while pushing those innovations toward commercialization so they could be broadly deployed across biomedical research programs.
Browse more opportunities from the same category: Health
Next opportunity: Development and Commercialization of Technologies to Create, Characterize or Improve Animal Models of Human Disease (SBIR)(R43/R44)
Previous opportunity: FY10 Railroad Highway Grade Crossing Mitigation,ICC
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 13 093
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 13 093) also looked into and applied for these:
| Funding Opportunity |
|---|
| Development and Commercialization of Technologies to Create, Characterize or Improve Animal Models of Human Disease (SBIR)(R43/R44) Apply for PA 13 092 Funding Number: PA 13 092 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Clinical and Public Health Curriculum Development, Training and Information Systems Support for the Haiti Health Care System under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH13 1331 Funding Number: CDC RFA GH13 1331 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $5,000,000 |
| Accelerating Delivery of Comprehensive HIV/AIDS in High Prevalence, Underserved Districts In The Republic Of Uganda Under The Presidents Emergency Plan For AIDS Relief (PEPFAR) Apply for CDC RFA GH13 1332 Funding Number: CDC RFA GH13 1332 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $5,203,759 |
| Capacity Strengthening to Support Provision of High Quality and Evidence based HIV Prevention, Care and Treatment Services to Staff and Family Members of the Kenya Prisons Services Staff, Family Members, and Prisoners in Kenya and Program Transition Apply for CDC RFA GH13 1308 Funding Number: CDC RFA GH13 1308 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,500,000 |
| Increasing HIV/AIDS Program Capacity through Human Resources Capacity Building to Support the Transition of the Kenya HIV Program to Local Organizations under the Presidents Emergency Plan for AIDS Relief (PEPFAR). Apply for CDC RFA GH13 1309 Funding Number: CDC RFA GH13 1309 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,000,000 |
| Technical Assistance for the Transition of Comprehensive HIV/AIDS Programs and Medical Education to Ethiopia under the Presidents Emergency Plan for AIDS Relief Apply for CDC RFA GH13 1310 Funding Number: CDC RFA GH13 1310 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $8,000,000 |
| Improving Public Health Practices and Service Delivery in the Federal Democratic Republic of Ethiopia with a Focus on HIV, Sexually Transmitted Infections, and Tuberculosis under the Presidents Emergency Plan for AIDS Relief Apply for CDC RFA GH13 1314 Funding Number: CDC RFA GH13 1314 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,500,000 |
| Strengthening Strategic Information Activities in the Kingdom of Lesotho under the Presidents Emergency Plan for AIDS Relief Apply for CDC RFA GH13 1315 Funding Number: CDC RFA GH13 1315 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,200,000 |
| Improving Implementation of Programs for Care Apply for CDC RFA GH13 1317 Funding Number: CDC RFA GH13 1317 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $1,000,000 |
| Technical assistance to accelerate the elimination of mother to child transmission (EMTCT) of HIV and improve HIV free child survival in the Republic of Zambia under the Presidents Emergency Plan for AIDS Relief Apply for CDC RFA GH13 1350 Funding Number: CDC RFA GH13 1350 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $10,000,000 |
| Strengthening Local Ownership for the Sustainable Provision of Comprehensive HIV/AIDS Services by the Health Bureaus of Amhara and Tigray Regional States of the Federal Democratic Republic of Ethiopia under the Presidents Emergency Plan for AIDS Reli Apply for CDC RFA GH13 1311 Funding Number: CDC RFA GH13 1311 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,500,000 |
| Strengthening Capacity for Laboratory Systems, Strategic Information, and Technical Leadership in Public Health for the National HIV/AIDS Response in the Federal Democratic Republic of Ethiopia under the Presidents Emergency Plan for AIDS Relief (PEP Apply for CDC RFA GH13 1313 Funding Number: CDC RFA GH13 1313 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $4,000,000 |
| Implementation of Integrated HIV/AIDS Treatment, Care and Prevention Programs in the Republic of Mozambique under the Presidents Emergency Plan for AIDS Relief Apply for CDC RGA GH13 1316 Funding Number: CDC RGA GH13 1316 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $5,000,000 |
| Clinical Sites for an Undiagnosed Diseases Network (UDN) (U01) Apply for RFA RM 13 004 Funding Number: RFA RM 13 004 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Implementation of Integrated HIV/AIDS Treatment, Care and Prevention Programs in the Republic of Mozambique under the Presidents Emergency Plan for AIDS Relief Apply for CDC RFA GH13 1316 Funding Number: CDC RFA GH13 1316 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $5,000,000 |
| Strengthening Community Care and Support Systems and Services (SCCSSS) in Namibia Apply for SOL 673 13 000002 Funding Number: SOL 673 13 000002 Agency: South Africa USAID Pretoria Category: Health Funding Amount: $9,000,000 |
| Indigenous Child Health Strong Communities, Healthy Children Apply for HHS 2013 IHS HPDP 0001 Funding Number: HHS 2013 IHS HPDP 0001 Agency: Indian Health Service Category: Health Funding Amount: $100,000 |
| Providing Information System Support for Training and Implementation of National HIV Monitoring Systems in the United Republic of Tanzania under the Presidents Emergency Plan for AIDS Relief Apply for CDC RFA GH13 1318 Funding Number: CDC RFA GH13 1318 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $320,000 |
| NIA Limited Competition Renewals of, and Revisions to, Existing Cooperative agreement Awards (U01) Apply for PAR 13 097 Funding Number: PAR 13 097 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Behavioral and Serological Survey (BSS) for HIV and Syphilis among Diamond Mine Workers in Angola Apply for CDC RFA GH13 1354 Funding Number: CDC RFA GH13 1354 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $500,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 13 093", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.